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Abstract 
Proteins that are modified by chemical conjugation require at least two separate purification 
processes. First the bulk protein is purified, and then after chemical conjugation, a second 
purification process is required to obtain the modified protein. In an effort to develop new 
enabling technologies to integrate bioprocessing and protein modification, we describe the use 
of disulfide-bridging conjugation to conduct PEGylation during protein refolding. Preliminary 
experiments using a PEG-mono-sulfone reagent with partially unfolded leptin and unfolded 
RNAse T1 indicated that the cysteine thiols underwent disulfide-bridging conjugation to give 
the PEGylated proteins.  Interferon-β1b (IFN-β1b) was then expressed in E.coli as inclusion 
bodies and found to undergo disulfide bridging-conjugation during refolding. The PEG-IFN-
β1b was isolated by ion-exchange chromatography and displayed in vitro biological activity. 
In the absence of the PEGylation reagent, IFN-β1b refolding was less efficient and yielded 
protein aggregates. No PEGylation was observed if the cysteines on IFN-β1b were first 
modified with iodoacetamide prior to refolding. Our results demonstrate that the simultaneous 
refolding and disulfide bridging PEGylation of proteins could be a useful strategy in the 
development of affordable modified protein therapeutics. 
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1. Introduction  
Proteins that are modified by chemical conjugation generally require at least two separate 
purification processes. The bulk protein must first be purified, and then after chemical 
conjugation, a second purification process is required to obtain the modified protein [1]. 
There are many protein modifications that are conducted for a wide range of applications in 
industry, and consumer and healthcare [2-4]. A clinically proven protein modification used on 
a wide range of proteins is the covalent conjugation of poly(ethylene glycol) (PEG) to a 
protein. Protein PEGylation increases the circulation time of the modified protein and has 
improved the clinical efficacy for several proteins [5-7] while also decreasing the propensity 
for protein aggregation [8-12]. Therapeutic proteins must meet stringent specifications for 
purity and their manufacture is often by batch processes that are complex and expensive. To 
simplify manufacturing, there is much ongoing effort to develop new enabling technologies to 
create continuous bioprocessing strategies, especially for downstream processing [13-16], e.g. 
the integration of protein refolding from inclusion bodies (IBs) and purification steps [17].  
There are many advantages to using E. coli for the production of proteins [18-24] (e.g. 
rapid growth and high yield), especially for non-glycosylated proteins (antibody fragments, 
some cytokines, novel protein scaffolds) which continue to be developed. Although not 
universally true [25], IBs can contain a high proportion of the target protein which is 
protected from proteolytic degradation [18, 26-27]. IBs can also be readily separated during 
early downstream processing. Unfortunately protein refolding from IBs often involves 
extensive optimisation and bioprocessing, but continuing improvements in IB solubilisation 
are resulting in better recoveries of the correctly folded protein [28]. Of the many additives 
that have been examined during protein folding from IBs, unconjugated PEG has also been 
used to suppress aggregation [29-32]. 
There is the possibility that covalently modifying a protein with PEG during refolding 
could be used to increase refolding recovery. If PEGylation during refolding can be achieved, 
then two separate purification processes for the starting protein and again for the PEGylated 
protein would not be necessary. The PEG modification step would be incorporated into the 
refolding process and less additives would be necessary for successful refolding to occur. 
Refolding of more hydrophobic proteins might be possible where the presence of the 
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conjugated PEG would impart steric shielding effects to minimise protein-protein interactions 
leading to aggregation. The PEGylation reagent must undergo efficient conjugation at a 
specific amino acid residue on the target protein for PEGylation to be conducted prior to the 
bulk protein first being purified or during refolding,  
We have developed hydrolytically stable, bis-alkylation PEGylation reagents 1 and 3 
(Figure 1A) that undergo conjugation with two cysteine sulfur atoms, derived from a reduced 
disulfide bond, to give a three-carbon bridge linking the cysteine thiols. This type of 
PEGylation is known as disulfide bridging PEGylation (Figure 1B) [33-35]. PEG-bis-sulfone 
1 first undergoes an elimination reaction in situ to generate the PEG-mono-sulfone 3 (Figure 
1A) which then undergoes conjugation with the protein by a sequence of addition-elimination 
reactions. Such reactions are known to be able to give a thermodynamically stable product 
[36]. The PEG-mono-sulfone 3 can be isolated and used directly. The reagent is much more 
selective for cysteine thiols than amines (e.g. N-terminus, residues of lysine, histidine, 
arginine) at pH values less than 8.0. Due to the reaction mechanism of the conjugation, PEG-
reagent 3 (Figure 1B) is able to produce the most stable product thermodynamically. Hence it 
was hoped the refolding process could be made more efficient by the presence of PEG and by 
the nature of the conjugation reaction.  
During refolding, disulfide bonds are usually formed by two thiol-disulﬁde exchange 
reactions with a redox reagent or another protein [37-38]. Disulfide bond formation is thought 
to occur after conformational ordering and partial folding of the protein [37-42]. Disulfide 
bond formation is thermodynamically coupled to the conformational folding of the protein 
[37-42]. Known as oxidative refolding, optimisation is often empirical requiring the judicious 
use of redox buffers and quenching conditions of the redox couple. The use of PEG-mono-
sulfone 3 avoids the need for oxidative refolding. Although attempts to integrate PEG 
modification during refolding or after partial protein unfolding have been described [34, 43-
48], there remains a fundamental need to examine more efficient and site-specific PEGylation 
reagents that would assist in the protein folding process.  
FIGURE 1 
Intially refolding PEGylation studies were conducted using PEG-mono-sulfone 3 with 
two model proteins, leptin and RNase T1 to evaluate the feasibility of our approach. We then 
describe PEGylation the during the refolding of interferon-beta 1b (IFN-β1b) which is 
clinically registered to treat multiple sclerosis and considered a difficult protein to refold. The 
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majority of the studies described here were conducted with PEG-mono-sulfone 3 that was 
derived from a 20 kDa PEG precursor (hence PEG20-mono-sulfone 3). IFN-β1b is produced 
from E. coli, however it is well known to be a hydrophobic protein [49-51] that can be 
difficult to refold from IBs [52]. IFN-β1b is a cytokine and is an example of an α-helical 
barrel protein, of which several are used clinically [53]. Several cytokines are also PEGylated 
and some are used as first line treatments for disease (e.g. PEGylated IFN-α2: Pegasys™ and 
PegIntron™; and PEGylated GCSF: Neulasta™ and Lonquex™). PEGylated interferon-beta 
1a (IFN-β1a), which is a glycosylated variant of IFN-β, was registered for clinical used in the 
USA in 2014 [53-55]. Preliminary refolding PEGylation experiments using the same PEG20-
mono-sulfone 3 (derived from 20 kDa PEG) were conducted with partially unfolded leptin, 
another α-helical barrel protein, and RNase T1. Although RNase T1 is not a cytokine, it has 
two disulfide bonds and is known to readily refold. Our hope was to determine whether any of 
the disulfide rebridged RNase could be obtained during folding.  
2. Materials & Methods 
2.1. Materials 
Recombinant lyophilized human leptin was purchased from Peprotech EC Ltd (cat no: 300-
27). RNase T1 (from aspergillus oryzae) was from Worthington Biochem (cat no: RT1S). 
SDS-PAGE analyses were conducted using an XCell Surelock Mini-Cell, precast 4-12% 
NuPAGE Bis-Tris gels and MOPs and MES running buffer, with Novex Sharp protein 
markers (Invitrogen). Gels were stained using Coomassie-based InstantBlue stain (Expedeon) 
and Silver Express® (Invitrogen). HiTrap SP FF cation, Q FF anion exchange and PD10 
protein desalting columns were supplied by GE Healthcare. PEG-bis-sulfone reagent 1 was 
supplied from PolyTherics Ltd and the reagent was treated (15 mg in 1 mL of 50 mM sodium 
phosphate buffer, pH 7.4) at ambient temperature overnight to give the PEG-mono-sulfone 3. 
MicroBCA assay and Ellman’s reagent were obtained from Thermo Scientific. UV 
measurements were obtained with a Hitachi U-2800A dual beam spectrometer and a Wallac 
Victor2 1420 plate reader. The A549 and Daudi cell lines, and encephalomyocarditis virus 
(EMCV) were obtained from the ATCC. Fetal bovine serum (FBS), RPMI 1640 media, 
Dulbecco's Modified Eagle Medium (DMEM), L-glutamine and penicillin/streptomycin were 
purchased from PAA laboratories. All other buffer components were purchased from Sigma 
Aldrich.  
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2.2. Methods 
2.2.1. Refolding PEGylation of RNase T1 
RNase T1 (0.45 mg/mL in 2.8 M ammonium sulfate, Worthington) was denatured by buffer 
exchange using a PD10 column into denaturing buffer (50 mM sodium phosphate 6 M 
guanidine hydrochloride (GuHCl; pH 7.8) and then DTT was added to give a concentration of 
50 mM. After incubation at ambient temperature for 30 min, the DTT was removed using a 
PD10 column into 100 mM Tris-HCl, pH 8.0 containing 1.9 M GuHCl and 0.4 M sodium 
chloride (NaCl). After a 45 min incubation at 4 °C, PEG20-mono-sulfone 3 (54.0 µL of a 15.0 
mg/mL solution; 1.0 equiv.) was added to this refolding protein solution and further incubated 
for 1 h 45 min at 4 °C. The reaction mixture was buffer exchanged into 20 mM Tris-HCl, pH 
8.0 and then loaded at a flow rate of 1 mL/min onto a Q FF column pre-equilibrated with the 
same buffer. The unconjugated PEG reagent eluted from the column first and then the 
PEGylated RNase was obtained using a multiple-step gradient from 0.2-0.4 M NaCl using 
0.02 M elution increments of 5 mL collecting 1 mL fractions. 
2.2.2. Activity assay for PEGylated RNase T1 
Substrate solution was prepared by dissolving 10 mg of yeast RNA in 1 mL of Tris buffer (50 
mM Tris-HCl, 2 mM EDTA, pH 7.5) [56]. Methylene blue buffer was prepared in an amber 
bottle by dissolving 1 mg of methylene blue hydrate in 100 mL of prepared Tris buffer. The 
absorbance of the prepared buffer solution at 688 nm was then checked and adjusted to 0.5 ± 
0.01 by the addition of further buffer. For the assay, 920 µL of methylene blue buffer was 
added to 80 µL of RNA substrate solution in 1.5 mL cuvettes. Cuvettes were then pre-
incubated in the dark for 10 min at 25 ºC to enable RNA/methylene blue complex formation. 
The reaction was then started by the addition of 10 µL volumes of different concentrations of 
RNase T1 (10, 5, 2.5 and 1.25 µg) and the PEGylated conjugate (10 µg). No RNase T1 was 
added to control cuvette. The change in absorbance at 688 nm was measured over 20 min by 
spectrophotometer. 
2.2.3. PEGylation and partial refolding of leptin  
Lyophilised leptin (Peprotech EC) was reconstituted in the reduction buffer (50 mM sodium 
phosphate, 20 mM EDTA, 2 M arginine mono-hydrochloride, pH 7.4). To the resulting 
solution was added 3.1 mg of dithiothreitol (DTT) to achieve a reductant concentration of 20 
mM and incubated for 30 min at 4 ºC. The reduced protein was then buffer exchanged by 
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means of a PD10 column into fresh reduction buffer to give a final volume of 2 mL. The 
PEG20-mono-sulfone 3 (5 mg/mL in 50 mM sodium phosphate, pH 7.4; 1.5 molar equiv.) was 
added to the reduced leptin and the solution was incubated overnight at 4 °C. Conversion of 
native leptin to mono-PEG-leptin was determined by densitometric analysis of the resulting 
gel bands using ImageQuant software. Purification was conducted using a HiTrap SP FF 
column. Prior to purification, the reaction mixture was buffer exchanged into the loading 
buffer (20 mM sodium acetate, pH 4.0) and then loaded (3.5 mL) onto a HiTrap SP FF 
column (1 mL). Unreacted PEG was removed from the column by washing with 5 column 
volumes (1 mL each) of the loading buffer. Separation of the PEG-leptin conjugate from the 
remaining reaction components was achieved using a linear gradient of 0-50% of 20 mM 
sodium acetate, pH 4.0 containing 1 M NaCl over 40 min at a flow rate of 1 mL/min. The 
identity of each of the peaks and the resulting fractions were characterised by SDS-PAGE. 
2.2.4. Expression and solubilisation of IFN-β1b inclusion bodies 
The plasmid harbouring the sequence for human IFN-β1b along with an eight-residue N-
terminal histidine tag (Gene Oracle) was amplified by polymerase chain reaction (PCR) using 
the following primers; forward 5′-CACCATGCATCACCACCATCATCATCAC-3′ and 
reverse 5′-TTATTAGTTACGAAGGTATCCTGTC-3′. The amplified gene was then ligated 
into the PET-101/D-TOPO vector (Invitrogen) and used to transform E. coli BL21 (DE3) 
cells. The presence of the inserted gene was confirmed by restriction enzyme digestion using 
XbaI and HindIII and by sequencing. A single E. coli colony containing the recombinant 
plasmid was selected and grown overnight in lysogeny broth (LB) at 37 °C shaking at 200 
rpm for the inoculum of the large-scale fermentation. E. coli containing the recombinant 
plasmid were grown in terrific broth (TB) (24 g/L yeast extract, 12 g/L tryptone, 4 mL/L 
glycerol, 3.31 g/L KH2PO4 and  12.54 g/L K2HPO4) at 37 °C on a shaking incubator at 200 
rpm in the presence of 100 µg/mL ampicillin until the OD at 600 nm reached 0.5. Induction 
was then carried out using 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). After 2.5 h of 
induction, the cells were harvested by centrifugation (Sorvall Legend RT+) at 2,500 g for 30 
min at 4 °C. Pelleted cells were resuspended in PBS containing 0.2 mg/mL lysozyme and 
0.02 mg/mL DNase, incubated with shaking at ambient temperature for 2 h, then lysed by 
sonication (QSonica Q500 with 1/2” diameter probe) for 2 min at 100% for 0.5 cycles. 
Sonication was then repeated twice. Soluble material was then isolated by centrifugation 
(2,500 g, 30 min at 4 °C) and pellets were washed with PBS/1% Triton-X100 (10 mL/g of 
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pellet) and left shaking overnight at 4 °C. Following another centrifugation step, the pellets 
were washed with PBS/1 mM TCEP (20 mL/g of pellet) and sonicated for 2 min at 100% for 
0.5 cycles, and the pellet recovered through centrifugation. This was followed by another 
washing (20 mL/g of 50 mM Tris, pH 8.0 containing 150 mM NaCl), sonication (1 M urea 
and 0.2% Triton-X100) and then centrifugation (5 mL/g of dH2O containing 2 mM EDTA). 
The washed inclusion bodies were then solubilised in 50 mM Tris-HCl, pH 8.0 containing 6 
M GuHCl, 2 mM EDTA and 20 mM DTT at a protein concentration of 10 mg/mL, heated to 
55 °C for 30 min, then allowed to cool overnight at ambient temperature. The solubilised 
inclusion bodies were then centrifuged (21,000 g, 45 min at 4 °C) to separate the soluble 
protein from the aggregates.  
2.2.5. PEGylation of IFN-β1b on refolding 
For PEGylation, the supernatant was buffer exchanged using a PD10 column into a refolding 
buffer (50 mM sodium phosphate, pH 7.8 containing 20 mM EDTA, 6 M GuHCl and 1 mg 
mL of n-dodecyl β-D-maltoside (DDM)). This step also served to remove the excess DTT that 
was used to solubilise the IBs. The concentration of the target protein in the prepared IBs was 
estimated using a human serum IFN-β1b ELISA kit. The concentration of the solubilised 
IFN-β1b inclusion bodies were then adjusted to 0.3 mg/mL by the addition of further 
denaturing buffer. Refolding was then carried out by a two-step dilution by the addition of the 
refolding buffer initially to 4 M GuHCl, then to 2 M GuHCl. Each dilution step was followed 
by an incubation at 4 °C for 4 h. To the prepared IBs was added 1 molar equivalent of 20 kDa 
PEG-bis-sulfone 1 (PEG20-bis-sulfone 1), which had been pre-activated overnight at 37 °C in 
50 mM sodium phosphate, pH 7.8 in order to generate the reactive mono-sulfone form of the 
reagent in situ (PEG-mono-sulfone 3). PEG20-IFN-β1b was then separated from other reaction 
components such as unreacted protein, unreacted PEG and multi-PEGylated species using ion 
exchange chromatography (IEC). The PEGylation reaction mixture was initially buffer 
exchange using a PD10 column into 50 mM sodium phosphate, pH 6.0 containing 0.1 mg/mL 
DDM. The buffer exchanged reaction mixture was then loaded onto the column (HiTrap SP 
FF) and the diPEG-IFN-β1b conjugate eluted from the column using 0.2 M NaCl while the 
mono-PEG-IFN-β1b conjugate was eluted using 0.26 M NaCl and any unreacted native IFN-
β1b was eluted with 0.4 M NaCl. Purity estimations were made by running each of the 
fractions on a 4-12% Bis-Tris SDS-PAGE gel and the concentration of the PEGylated 
conjugate was determined by UV and microBCA assay.  
 9 
2.2.6. Western blot analysis 
Reaction mixtures were analysis by 4-12% Bis-Tris SDS-PAGE and transferred onto 
nitrocellulose membranes using a XCell II™ Blot Module CE Mark (Invitrogen) for 1 h at 30 
V. The membrane was then blocked for 1 h at ambient temperature using PBS supplemented 
with 0.1% Tween-20 (PBS/T) with 5% w/v dried skimmed milk. Blots were incubated with 
rabbit anti-IFN-β primary antibody (1/1000 dilution) for 1 h at ambient temperature and then 
with anti-rabbit alkaline phosphate (AP) conjugated secondary antibody (1/5000 dilution) 
(both from Abcam) for another 1 h at ambient temperature. The target protein was then 
detected using Sigma BCIP®/NBT tablets.  
2.2.7. In vitro bioactivity of PEGylated and refolded IFN-β1b 
The activity of the refolded and PEGylated was assessed by antiviral assay based on the 
ability of IFN-β1b to protect human lung carcinoma (A549) cells from the cytopathic effects 
of the encephalomyocarditis virus (EMCV). The A549 cell line was maintained in DMEM 
media supplemented with 10% fetal bovine serum (FBS), 50 units/mL penicillin, 50 units/ mL 
of streptomycin and 2 mM L-glutamine at 37 °C in a humidified atmosphere of 5% CO2. For 
the purpose of the antiviral assay cells were resuspended at a concentration of 1.7 × 106 
cells/mL and 50 µL of the cell suspension was seeded into the wells of a 96-well flat bottom 
microtitre plate. Following overnight incubation at 37 °C two-fold serial dilutions of each of 
the test samples were added to the wells in duplicate. The plates were then incubated at 37 °C 
for 24 h. The media was removed from the plates and 50 µL of 1.6 × 105 PFU/mL solution of 
EMCV in DMEM/2% FBS was added to each well. A positive control with cells and EMCV 
only and a negative control of just cells were also prepared on each plate. The following day 
cells in the positive control wells were visually inspected until ~80% of the cells appeared 
dead. Wells were washed twice with 150 µL sterile PBS and cell viability was then assessed 
by staining with 50 µL of 4% formaldehyde/0.1% methyl violet 2B for 30 min. Plates were 
washed twice with 150 µL PBS and allowed to air dry before the remaining dye was 
solubilised in 50 µL of 2% SDS by agitation and the absorbance at 570 nm was measured on 
a plate reader. 
The antiproliferative activity of the PEGylated IFN-β1b conjugate using a bioassay 
based on the ability of IFN-β1b to inhibit the proliferation of the human Burkitt’s lymphoma 
(Daudi) cell line. Daudi cells were maintained in RPMI media containing 10% FBS and 50 
units/mL penicillin and 50 units/mL of streptomycin in a humidified atmosphere of 5 % CO2 
 10 
at 37°C. For the assay, Daudi cells were seeded into 96-well U-bottom plates at a density of 
104 cells per well in 100 µL. To each well was added 3-fold serial dilutions of each of the 
samples and standards in duplicate. Cells were then allowed to grow for 72 h at 37 °C before 
the addition of 20 uL MTT to each well (5 mg/mL in PBS sterile-filtered using a 0.22 µm 
syringe filter). After a 3 h incubation at 37 °C, plates were centrifuged at 1,500 g for 10 min 
in order to pellet the dye. The media was aspirated from each well using a multi-channel 
pipette and the dye was solubilised in 100 µL DMSO. Finally, the absorbance of each was 
read at 570 nm using a plate reader. 
2.2.8. MALDI- TOF mass spectrometry 
All samples were buffer exchanged into 10 mM ammonium bicarbonate, pH 8.0 using 
desalting spin columns prior to analysis. Mass analysis was carried out by matrix-assisted 
laser desorption time of flight mass spectrometry (MALDI-TOF) using an Applied 
Biosystems DE-PRO instrument with a nitrogen laser. The matrix was 20 mg/mL sinapinic 
acid in a 50:50 mixture of acetonitrile:water and 0.1% trifluoroacetic acid (TFA). Sample and 
matrix were mixed at a ratio of 1:1 and 1 µL spotted onto a 100-well sample plate. Mass 
spectra were acquired in positive ion mode against an internal standard of bovine carbonic 
anhydrase. Low molecular mass species (600-2,500 Da) were observed using the high-
resolution reflectron mode (20 kV accelerating voltage, 350 ns extraction delay time) and 
high molecular mass species (2-100 kDa) were observed using the low-resolution linear mode 
(25 kV accelerating voltage, 750 ns extraction delay time).  
2.2.9. Tryptic digestion and MALDI-TOF mass spectrometry 
Sequence grade modified trypsin (Promega) was solubilised in 50 mM acetic acid to a 
concentration of 0.2 mg/mL. To samples of both the native protein and the mono-PEG-IFN-
β1b conjugate were added a 1:20 ratio of trypsin to protein and incubated at 37°C for 
approximately 16 hours. Samples were then analysed by MALDI-TOF mass spectrometry 
according to method outlined above. 
2.2.10. Stability studies 
Aliquots of samples in 50 mM sodium phosphate, pH 7.4 were stored up to 4 weeks at 37 °C. 
Sample stability was then assessed by SDS-PAGE analysis using both Coomassie InstantBlue 
and barium iodide staining. 
 11 
3. Results 
3.1. Refolding PEGylation of RNase T1. 
 The two disulfide bonds of RNase T1 were reduced in denaturing conditions and the protein 
refolded by buffer exchange into 0.1 M Tris-HCl, pH 8.0, containing 1.9 M GuHCl and 0.4 M 
NaCl. Using an enzymatic assay based upon the degradation of yeast RNA, the activity of 
RNAse T1 after refolding averaged 98.5% (n=3). RNase T1 was then refolded in the same 
solution during which 1 equivalent of PEG20-mono-sulfone 3 (derived from 20 kDa PEG) was 
added to the refolding solution 90 minutes after the start of the refolding process. Formation 
of the PEG20-RNase conjugate was observed (Figure 2, Lane 5). PEG migrates at 
approximately double its actual molecular weight compared to the protein molecular weight 
standards typically used in SDS-PAGE, i.e. PEG20 band appears at approximately 40 kDa. 
This characteristic of PEG migration is maintained when PEG is conjugated to a protein. 
Since the molecular weight of RNase T1 is 11 kDa, the band at approximately 50 kDa is 
consistent with that expected for PEG20-RNase conjugate (Figure 2, Lane 5). The gel was first 
stained with Coomassie InstantBlue stain to detect protein within the conjugate (Figure 2, 
Lane 4) and then barium iodide to detect PEG species. The band at 50 kDa was stained for 
both protein and PEG (Figure 2, Lane 5). Trace di-PEG20-RNase and unconjugated RNase 
were also observed. Ion exchange chromatography was used to purify the PEG20-RNase 
conjugate (Figure 2, Lane 7) and the in vitro activity was determined to be 23% (n=3). Earlier 
addition of the PEG20-mono-sulfone 3 to the refolding mixture resulted in the formation of 
more multi-PEGylated species (37% conversion to the mono-PEG species at 30 min). Later 
addition of PEG20-mono-sulfone 3 resulted in reduced conversion to the PEG20-RNase 
conjugate (54% at 60 min compared to 42%, 14% and 4% at 90, 120 and 150 min 
respectively).  
FIGURE 2 
3.2. Partial refolding PEGylation of leptin. 
 Leptin is a α-helical barrel protein with one disulfide bond located between a helix and a 
flexible loop. Preliminary experiments [35] showed that leptin could be PEGylated with 
PEG20-bis-sulfone 1 in the presence of arginine, which was necessary to suppress leptin 
aggregation after disulfide reduction. Partial reduction of other cytokines (e.g. IFN-α2) with 
the cysteines located in or near a helix does not result in the aggregation that is observed with 
 12 
leptin [34]. This is presumably due the location of the disulfide cysteines in or close to the 
helices and to the greater hydrophobic interactions between the helices to help maintain the 
tertiary structure after disulfide reduction. For this current study we wanted to explore the use 
of PEG20-mono-sulfone 3 to determine whether this reagent would effectively undergo 
disulfide-bridging conjugation with partially unfolded leptin.  
Disulfide reduced leptin was found to precipitate from solution in the absence of 
arginine with no formation of the PEG20-leptin conjugate (Figure 3A, lane 4). In the presence 
of 2 M arginine hydrochloride and using 1.5 eq. of PEG20-mono-sulfone 3, the desired PEG20-
leptin product was formed in good conversion (~55%) (Figure 3A, lanes 5-6). Trace amounts 
of higher molecular weight PEGylated products were also observed (Figure 3A, lanes 5-6) 
using these conditions. No conjugation was observed when the PEG20-mono-sulfone 3 was 
added to leptin that had not been previously incubated with DTT (Figure 3A, lane 7). Ion 
exchange chromatography was used to purify PEG20-leptin (Figure 3A, lane 8) and the 
conjugate was stable with no evidence of de-PEGylation when stored in 50 mM sodium 
phosphate, pH 7.4 for up to 4 weeks at 37 °C (Figure 3A, lane 9). No free thiols were detected 
by Ellman’s assay following DTT treatment of the PEG20-leptin conjugate.  
FIGURE 3 
The MALDI-TOF (Figure 3B) of the PEG20-leptin conjugate (Figure 3A, lane 8) was 
~37 kDa which is the expected mass for PEG20-leptin. Proteins that are conjugated to PEG do 
not display a single molecular weight in MALDI-TOF because the PEG precursors that are 
used to make PEGylation reagents are narrowly dispersed. These PEG precursors often have 
molecular weights that range from about 5% above and below the stated molecular weight. 
The expected peptide fragments for the proteolytic digestion of leptin without prior 
treatment with DTT are shown in Figure 3C. Fragment 11 with the intact disulfide has a 
molecular weight of 5510.1 Da. Trypsin digestion of PEG20-leptin gave a single fragment 
with a conjugated PEG (Figure 3A, lane 10). No evidence was observed to suggest the 
existence of other lower molecular weight PEGylated fragments. The molecular weight of the 
PEG20-peptide fragment was approximately 25 kDa (Figure 3D), which is consistent for the 
PEG fragment 12 (Figure 3C) derived from the 20 kDa PEG-mono-sulfone 3.  
3.3. Expression of IFN-β1b and refolding PEGylation from inclusion bodies.  
Expression of (IFN-β1b) was induced for 2.5 h by the addition of 1 mM IPTG to the shake 
flask culture. A band could be seen in the SDS-PAGE gel of both the crude extract and pellet 
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fractions that corresponded to the predicted size of IFN-β1b (21.4 kDa; 174 aa) (Figure 4A, 
lanes 1 & 3). No protein was visualised in the supernatant, indicating that the IFN-β1b was 
expressed solely in the IB form (Figure 4A, lane 2). A 1 L fermentation yielded a total of 21.1 
g of wet pellet, which after five washing steps gave approximately 2.5 g of IBs that were 
relatively pure in IFN-β1b (Figure 4A, lane 4). An anti-IFN-β1b western blot (Figure 4B, lane 
6) was consistent for the presence of IFN-β1b in the IBs. 
FIGURE 4  
Different refolding strategies in the presence of PEG20-mono-sulfone 3 were 
examined. Dilution of IFN-β1b in the presence of anti-aggregation additives (e.g. Tween-20, 
Triton X-100, Expedeon NV10 and n-dodecyl β-d-maltoside (DDM)) gave the most 
promising results. Other methods of refolding such as on-column and dialysis were also 
tested, but both gave a lower yield and more variable results compared to the dilution method. 
Refolding conditions were also optimised in terms of the reaction temperature, pH, number of 
equivalents of the PEG20-mono-sulfone 3, timing of PEG addition, number of dilution steps 
and refolding time. PEGylation and refolding were conducted in the presence of PEG20-mono-
sulfone 3 (1 equiv.) and DDM (1 mg/mL) to give a good conversion of PEG20-IFN-β1b with 
little observable unreacted IFN-β1b (Figure 4B, lanes 3-4) or multi-PEGylated protein 
species. Of the different additives that were examined to prevent protein aggregation, DDM 
was found to give a higher PEGylation conversion. This additive has been reported as being 
an effective aggregation suppressant for IFN-β1b [57]. The 6 M GuHCl that was present did 
not appear to hinder the PEGylation reaction. Reactions were also conducted using PEG20-
bis-sulfone 1 and the formation of PEG20-IFN-β1b was also observed.  
Anti-IFN-β1b western blot (Figure 4B, lane 7) was consistent with the formation of 
PEG20-IFN-β1b. Ion exchange chromatography was effective to purify the PEGylated IFN-
β1b species from unconjugated PEG reagent and other cellular proteins (Figure 4B, lane 8). 
The total yield of PEG20-IFN-β1b (600 µg in IFN-β1b) following this single step of 
purification was ~12% as determined by UV and microBCA protein assay. This yield is 
considered to be very good when compared to the process flow of conventional purification of 
the bulk protein, modification and then purification of the modified protein. 
No non-specific conjugation was observed in the presence of PEG20-mono-sulfone 3 
when iodoacetamide had first been used to block the cysteine residues (Figure 4B, lane 5). 
When no PEG reagent was added to the refolding reaction, no refolded protein could be 
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recovered. It was also discovered that the timing for the addition of the PEG20-mono-sulfone 3 
reagent is important to maximise the yield of PEG20-IFN-β1b during refolding. Addition of 
PEG-mono-sulfone 3 at 4 h appeared to be the optimal timepoint to obtain the mono-PEG20-
IFN-β1b conjugate.  Early addition of the PEG-mono-sulfone 3 (0 to 3 h) to the refolding 
solution tended to result in the formation of a di-PEG20-IFN-β1b conjugate, which was 
thought to be the unbridged conjugate with one PEG conjugated to each cysteine thiol. Later 
addition of the reagent (after 5 h up to 7 h) failed to yield any PEGylated product.   
Use of an equivalent mass of PEG 400 (50 protein equivalents) in an effort to refold 
IFN-β1b in the absence of the PEG20-mono-sulfone 3 did not give refolded IFN-β1b. 
Although the majority of the work in this study was done with the 20 kDa PEG-mono-sulfone 
3, both 10 kDa and 30 kDa PEG-mono-sulfones 3 also resulted in the formation of the 
corresponding PEG-IFN-β1b conjugate during refolding of IFN-β1b.  
The purified PEG20-IFN-β1b conjugate was incubated for up to 4 weeks at 37 °C in 
PBS, pH 7.4, and there was no evidence of free PEG following barium iodide staining or any 
free IFN-β1b by SDS-PAGE (Figure 4B, Lane 8). No de-PEGylation was observed when the 
PEG20-IFN-β1b conjugate was incubated in the presence of 10 mM DTT for 15 min at 
ambient temperature. No free protein thiol was observed by Ellman’s assay of the PEG20-IFN-
β1b conjugate following DTT treatment. 
The mass of the PEG20-IFN-β1b conjugate as determined by MALDI-TOF analysis 
was 41.2 kDa, an increase of ~20 kDa over the expected mass of the native protein (21.4 kDa) 
(Figure 4C). The purified PEG20-IFN-β1b conjugate was subjected to tryptic digestion to give 
a band for a fragment at approximately 40-45 kDa that could be detected by barium iodide 
staining. (Figure 4B, Lane 10). Mass spectral analysis of the digestion mixture gave one broad 
signal at 21.2 kDa, which was consistent with fragment 20 (Figure 4D-E).  
The activity of the PEG20-IFN-β1b conjugate was evaluated using an antiviral assay 
based on the ability of IFN-β1b to protect A549 cells from the effects of the 
encephalomyocarditis virus (EMCV) (Figure 5A). The PEG20-IFN-β1b conjugate was found 
to have an ED50 value of 389 ± 32 pg/mL while the unmodified IFN-β1b (NIBSC standard) 
had an ED50 of 2 ± 0.1 IU/mL (n=4). A Daudi-based antiproliferative assay showed that the 
PEG20-IFN-β1b conjugate (Figure 5B) displayed an ED50 value of 2688 ± 301 pg/mL and the 
unmodified IFN-β1b (NIBSC standard) displayed an ED50 value of 292 ± 30 IU/mL (n=4).  
FIGURE 5 
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4. Discussion 
4.1. Refolding driven by disulfide bridging conjugation 
Therapeutic proteins often have an accessible disulfide bond. Disulfides [40, 58], especially 
accessible disulfides [59], can act to increase the stability of the folded protein. The reaction 
mechanism for conjugation (Figure 1B) via an addition-elimination pathway provides the 
means to produce the thermodynamically most stable product [36]. This results in the 
conjugation of PEG via formation of a three-carbon bridge between the two cysteine thiols 
derived from a native disulfide [33-35]. The thermodynamic nature of the disulfide re-
bridging reaction is potentially valuable to help drive refolding without the need for redox 
couples during the refolding process while also simultaneously modifying the protein. 
Introduction of the PEG-mono-sulfone 3 to the refolding solutions of RNase and IFN-β1b was 
conducted when these proteins were partially refolded.  Although many competing reactions 
remain possible, our observations indicate that the disulfide bridging PEGylation was able to 
occur as the protein completed its refolding.  
We have also shown previously with several examples that disulfide bridging 
conjugation yields biologically active protein and that the thiol ether bonds in the conjugate 
are more stable than the original disulfide [33-35, 60-62]. Secreted proteins that are prepared 
from different sources are also purified before chemical modification. We anticipate our 
reagents would also be useful to modify secreted proteins early in their initial purification 
process in an analogous way to the modification of proteins during refolding from inclusion 
bodies.  
Other methods of conjugation generally, and PEGylation specifically, do not target the 
two cysteine thiols of a native disulfide bond. These other conjugation methods are not 
involved in the aspect of protein folding that is related to the formation of covalent bonds 
between amino acid residues. In the case of difficult-to-fold proteins such as IFN-β1b, we 
wanted to show that the concept of disulfide bridging conjugation could also be used to aid 
the folding process. The presence of PEG on the conjugation reagent would also be 
advantageous to drive refolding since it is known that PEG additives can be used during 
refolding to suppress aggregation [29-32] and these favourable effects may be enhanced once 
PEG is site-specifically conjugated to the protein. 
4.2. Reagent stability in refolding conditions 
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Dilution-based refolding was used in our studies because it is a simple and widely used 
method for small-scale refolding studies and has been scaled for use in protein manufacture. 
Although we recognise that refolding processes vary widely with each protein, our intent was 
to establish if PEGylation could be accomplished during refolding without substantially 
modifying what would be considered to be typical refolding conditions. Therefore, denaturant 
(6 M GuHCl) was used in our refolding experiments in the presence of only a small 
stoichiometric excess of the PEGylation reagent 1 or 3 (typically 1-2 equivalents). In spite of 
the high levels of denaturant present in the refolding buffer, the hydrolytic stability and thiol 
selectivity of reagents 1 and 3 are important characteristics to allow refolding PEGylation to 
be possible. The use of a slight stoichiometric excess of the reagent is also an important 
criterion to consider the potential scalability of our strategy. Results also indicated that the 
efficiency of PEGylation was improved when the refolding conjugation reactions were 
conducted in the presence of an aggregation suppressant. While the refolding conjugation 
conditions can be further optimised, it was gratifying that (i) the reagent was not consumed in 
these conditions, (ii) that PEGylation was observed and (iii) the PEGylated protein could be 
purified, isolated and characterised.  
4.3. Reagent thiol selectivity maintained in refolding conditions 
Thiol selectivity for reagent 1 (and thus reagent 3) is well established [33-35, 60, 62-63]. 
Characterisation of the refolding PEGylation of leptin with reagent 3 is consistent with 
PEGylation on the leptin cysteine thiols (Figure 3). When the expressed IFN-β1b was pre-
treated with iodoacetamide to cap the cysteine thiols, no PEGylation was observed. RNase T1 
is a protein with two disulfide bonds and we found that it was possible to tailor the reactions 
to favour the PEGylation of only one disulfide bond by adding the PEG later in the refolding 
process when the disulfide formation had already started. By fully unfolding the protein there 
is potential for both disulfide scrambling as well as the generation of multi-PEGylated species 
especially in the case of proteins containing multiple disulfide bonds. The use of small 
excesses of PEG such as those utilised here would also decrease the potential for any 
intermolecular crosslinking reactions that could occur between proteins and instead favor the 
formation of the proteins disulfide bridge. Typically PEGylation with reagent 1 is conducted 
on a fully folded protein after reduction of the accessible disulfide bond. Under these 
conditions the cysteine thiols remain spatially close. It is remarkable that a fully unfolded 
protein with more than one reduced disulfide bond can undergo disulfide bridging 
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PEGylation. Using this method the desired conjugate could be isolated from the reaction 
mixture with good purity using only a single purification step.  
4.4. Maintenance of biological activity 
Some loss of biological activity is expected for PEGylation as a result of PEG shielding 
effects [7], which causes a decrease in the rate of association during binding to the target 
ligand or receptor [60, 64]. For many proteins the existence of biological activity is a good 
indication of correct folding.  Where the formation of the protein’s disulfide bond is intrinsic 
to the biological activity, as in the case of RNase T1 and IFN-β1b, this can be used to further 
corroborate that PEG conjugation by disulfide rebridging has occurred. However, since 
PEGylation was conducted during protein folding, it is possible that some misfolded modified 
protein was present.   
4.5. Conclusion 
In conclusion, there is a continued need to simplify the processes used to obtain protein 
therapeutics. The PEG-mono-sulfone 3 can be used during protein refolding to undergo 
disulfide rebridging conjugation. Many protein therapeutics require PEGylation, or other 
modification, to improve clinical efficacy. Conducting PEG modification with site specific 
reagents that can be used before the protein is purified while also driving refolding has the 
potential to be used to develop continuous, more efficient and cost-effective protein 
manufacturing processes. The refolded PEGylated proteins described in this study could be 
purified by ion exchange chromatography and retained biological activity. While refolding is 
very protein specific, the disulfide rebridging approach has the potential to be further 
developed for disulfide-containing therapeutic proteins.  
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Figure legends 
Figure 1. (A) The PEG20-bis-sulfone 1 (R1= aryl and R2=tolyl) can undergo cysteine thiol 
specific conjugation at both of the β carbons. The conjugation sequence starts after 
elimination of toluene sulfinic acid anion 2 to give the PEG20-mono-sulfone 3 which has an 
α,β-double bond to a carbonyl. (B) Mechanistically, bis-alkylation occurs by a sequence of 
addition-elimination steps thought to be thermodynamically driven. Elimination of a second 
equivalent of sulfinic anion 2 (i.e. R2SO2-) is thought to occur after the first conjugation 
reaction and this generates a new α,β-double bond for the second conjugation to occur with a 
second cysteine sulfur atom resulting in disulfide bridged PEGylation.  
Figure 2. SDS-PAGE gel (Novex 4-12% Bis-Tris) showing the refolding PEGylation 
reaction between RNase T1 and PEG20-mono-sulfone 3. The molecular weight of the PEG in 
the reagent was 20 kDa. SDS-PAGE migration of PEG is approximately double its actual 
molecular weight compared to protein molecular weight standard of equivalent size. The gel 
was stained with Coomassie InstantBlue stain to detect protein and then barium iodide (*) to 
detect PEG species. Lane M, molecular weight standards; lane 1, native RNase T1; lane 2, 
reduced and denatured RNase T1; lane 3, PEG20-mono-sulfone 3; lane 4, reduced and 
denatured RNase T1 refolded in the presence of PEG20-mono-sulfone 3 (1 equiv.); lane 5, 
sample from lane 4 that was stained with barium iodide after Commassie blue stain; lane 6, 
control reaction with non-reduced RNase T1 in 6 M GuHCl + 1 equiv. of PEG20-mono-
sulfone 3; lane 7, IEC purified PEG20-RNase T1.  
Figure 3. (A) SDS-PAGE gel (Novex 12% Bis-Tris) of the reaction between leptin and 
PEG20-mono-sulfone 3 (derived from 20 kDa PEG) stained with Coomassie InstantBlue and 
silver stain (•) to detect protein and then barium iodide (*) to detect PEG species. Lane M, 
molecular weight standards; lane 1, native leptin; lane 2, reduced leptin; lane 3, PEG20-mono-
sulfone 3; lane 4, PEGylation reaction mixture: reduced leptin + PEG20-mono-sulfone 3 (1.5 
equiv.) in the absence of arginine; lanes 5-6, PEGylation reaction mixture: reduced leptin + 
PEG20-mono-sulfone 3 (1.5 equiv.) in the presence of 2 M arginine stained with Coomassie 
blue and barium iodide respectively; lane 7, control reaction comprised of non-reduced Leptin 
+ PEG20-mono-sulfone 3 (1.5 equiv.); lane 8, IEC purified PEG20-leptin; lane 9, PEG20-leptin 
after incubation at 4 °C for 28 days; lane 10, PEG20-leptin after 16 h incubation with 1:20 
ratio of trypsin to protein. (B) MALDI-TOF mass spectrum of the purified PEG20-leptin 
conjugate. (C) Table of possible fragments generated after tryptic digestion of PEG20-leptin. 
(D) Low-resolution linear mode MALDI-TOF spectrum of digested PEG20-leptin showing the 
PEG20-peptide fragment at approximately 25,042 Da which is consistent with fragment 12. 
Figure 4. (A) SDS-PAGE (Novex 4-12% Bis-Tris) analysis of the IFN-β1b expression 
fractions. Lane M, molecular weight standards; lane 1, crude extract after induction; lane 2, 
supernatant after induction; lane 3, pellet after induction; lane 4, washed pellet. (B) SDS-
PAGE gel (Novex 4-12% Bis-Tris) showing the results of the refolding PEGylation reactions. 
Staining accomplished with Coomassie InstantBlue and silver stain (•) to detect protein and 
then barium iodide (*) to detect PEG species. Lane M, molecular weight standards; lane 1, 
solubilised IFN-β1b inclusion bodies; lane 2, PEG20-mono-sulfone 3; lane 3, dilution 
refolding IFN-β1b in the presence of PEG20-mono-sulfone 3 (1 equiv.); lane 4, sample from 
lane 3 that was stained with barium iodide after Commassie blue stain; lane 5, pre-treatment 
of IFN-β1b with iodoacetamide (2 equiv.) followed by dilution refolding of IFN-β1b in the 
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presence of PEG20-mono-sulfone 3 (1 equiv.); lane 6, anti-IFN-β1b western blot of IFN-β1b 
inclusion bodies; lane 7, anti-IFN-β1b western blot of the refolding mixture IFN-β1b in the 
presence of PEG20-mono-sulfone 3 (1 equiv.); lane 8, IEC purified PEG20-IFN-β; lane 9, 
PEG20-IFN-β1b after incubation at 37 °C for 28 days in 50 mM sodium phosphate, pH 7.4 at 
1 mg/mL; lane 10, PEG20-IFN-β1b after 16 h incubation at 37 ˚C with a 1:20 ratio of trypsin 
to protein. (C) MALDI-TOF mass spectrum of the purified PEG20-IFN-β1b conjugate. (D) 
Table of possible fragments generated after tryptic digestion of PEG20-IFN-β. (E) Low-
resolution linear mode MALDI-TOF spectrum of digested refolded PEG20-IFN-β1b showing 
the PEG20-peptide fragment that is consistent with fragment 20. The peak at 23.3 kDa can be 
attributed to a small amount of residual trypsin. 
Figure 5. In vitro bioactivity of NIBSC IFN-β1b (●) and the 20 kDa refolded and PEGylated 
IFN-β1b conjugate (▲) as assessed using by (A) antiviral and (B) antiproliferative assays. 
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